Press "Enter" to skip to content

Diabetes Care Drugs Market 2019: Comprehensive Analysis by Top Key Companies, Industry Growth, Size, Share, Market Insights, Sales Volume and Forecast to 2024

Diabetes

The “Diabetes Care Drugs Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Diabetes Care Drugs Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Diabetes Care Drugs market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Diabetes Care Drugs Market Are:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Takeda
  • Pfizer
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck and Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14244205

    Market Overview:

  • – The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
  • – North America dominates the market, followed by Asia-Pacific.
  • – Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body’s cells do not respond properly to insulin (known as Type 2 diabetes), or both.
  • – Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.

    Scope of the Report:

  • The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.

    Diabetes Care Drugs Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Diabetes Care Drugs market?
    • What are the key market trends impacting the growth of the global Diabetes Care Drugs market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Diabetes Care Drugs market?
    • What are the market opportunities and threats faced by the vendors in the global Diabetes Care Drugs market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Diabetes Care Drugs market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14244205

    Key Market Trends:

    Rising Prevalence of Diabetes

    – As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
    – Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
    – Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
    – Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
    – The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.

    The United States Leads the Diabetes Drugs Market in North America

    – In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
    – In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Diabetes Care Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Diabetes Care Drugs.

    Purchase this Report (Price 6000 USD for single user license) – https://www.industryresearch.co/purchase/14244205

    Report Objectives:

    • Analyzing the size of the Diabetes Care Drugs market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Diabetes Care Drugs market.
    • Determining the key dynamics of the Diabetes Care Drugs market.
    • Highlighting significant trends of the Diabetes Care Drugs market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Diabetes Care Drugs market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Diabetes Care Drugs market.

    Detailed TOC of Diabetes Care Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Oral Anti-diabetic drugs (Value and Volume 2012-2024)
    5.1.1.1 Biguanides
    5.1.1.1.1 Metformin
    5.1.1.2 Alpha-Glucosidase Inhibitors
    5.1.1.3 Dopamine -D2 Receptor Agonist
    5.1.1.3.1 Cycloset (Bromocriptin)
    5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
    5.1.1.4.1 Invokana (Canagliflozin)
    5.1.1.4.2 Jardiance (Empagliflozin)
    5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4.4 Suglat (Ipragliflozin)
    5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    5.1.1.5.1 Januvia (Sitagliptin)
    5.1.1.5.2 Onglyza (Saxagliptin)
    5.1.1.5.3 Tradjenta (Linagliptin)
    5.1.1.5.4 Vipidia/Nesina (Alogliptin)
    5.1.1.5.5 Galvus (Vildagliptin)
    5.1.1.6 Sulfonylureas
    5.1.1.7 Meglitinides
    5.1.2 Insulins (Value and Volume 2012-2024)
    5.1.2.1 Basal or Long-acting Insulin
    5.1.2.1.1 Lantus (Insulin Glargine)
    5.1.2.1.2 Levemir (Insulin Detemir)
    5.1.2.1.3 Toujeo (Insulin Glargine)
    5.1.2.1.4 Tresiba (Insulin Degludec)
    5.1.2.1.5 Basaglar (Insulin Glargine)
    5.1.2.2 Bolus or Fast-acting Insulin
    5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    5.1.2.2.2 Humalog (Insulin Lispro)
    5.1.2.2.3 Apidra (Insulin Glulisine)
    5.1.2.3 Traditional Human Insulin
    5.1.2.3.1 Novolin/Actrapid/Insulatard
    5.1.2.3.2 Humulin
    5.1.2.3.3 Insuman
    5.1.2.4 Biosimilar Insulin
    5.1.2.4.1 Insulin Glargine Biosimilars
    5.1.2.4.2 Human Insulin Biosimilars
    5.1.3 Non-insulin Injectable drugs (Value and Volume 2012-2024)
    5.1.3.1 GLP-1 Receptor Agonists
    5.1.3.1.1 Victoza (Liraglutide)
    5.1.3.1.2 Byetta (Exenatide)
    5.1.3.1.3 Bydureon (Exenatide)
    5.1.3.1.4 Trulicity (Dulaglutide)
    5.1.3.1.5 Lyxumia (Lixisenatide)
    5.1.3.2 Amylin Analogue
    5.1.3.2.1 Symlin (Pramlintide)
    5.1.4 Combination Drugs
    5.1.4.1 Combination Insulin
    5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
    5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
    5.1.4.2 Oral Combination
    5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 Oral Anti-diabetic Drugs
    5.2.1.1.2 Insulin
    5.2.1.1.3 Non-Insulin Injectable Drugs
    5.2.1.1.4 Combination Drugs
    5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 Oral Anti-diabetic Drugs
    5.2.1.2.2 Insulin
    5.2.1.2.3 Non-Insulin Injectable Drugs
    5.2.1.2.4 Combination Drugs
    5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 Oral Anti-diabetic Drugs
    5.2.1.3.2 Insulin
    5.2.1.3.3 Non-Insulin Injectable Drugs
    5.2.1.3.4 Combination Drugs
    5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 Oral Anti-diabetic Drugs
    5.2.2.1.2 Insulin
    5.2.2.1.3 Non-Insulin Injectable Drugs
    5.2.2.1.4 Combination Drugs
    5.2.2.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 Oral Anti-diabetic Drugs
    5.2.2.2.2 Insulin
    5.2.2.2.3 Non-Insulin Injectable Drugs
    5.2.2.2.4 Combination Drugs
    5.2.2.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 Oral Anti-diabetic Drugs
    5.2.2.3.2 Insulin
    5.2.2.3.3 Non-Insulin Injectable Drugs
    5.2.2.3.4 Combination Drugs
    5.2.2.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 Oral Anti-diabetic Drugs
    5.2.2.4.2 Insulin
    5.2.2.4.3 Non-Insulin Injectable Drugs
    5.2.2.4.4 Combination Drugs
    5.2.2.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.5 United Kingdom (Value and Volume 2012-2024)
    5.2.2.5.1 Oral Anti-diabetic Drugs
    5.2.2.5.2 Insulin
    5.2.2.5.3 Non-Insulin Injectable Drugs
    5.2.2.5.4 Combination Drugs
    5.2.2.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 Oral Anti-diabetic Drugs
    5.2.2.6.2 Insulin
    5.2.2.6.3 Non-Insulin Injectable Drugs
    5.2.2.6.4 Combination Drugs
    5.2.2.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 Oral Anti-diabetic Drugs
    5.2.2.7.2 Insulin
    5.2.2.7.3 Non-Insulin Injectable Drugs
    5.2.2.7.4 Combination Drugs
    5.2.2.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 Oral Anti-diabetic Drugs
    5.2.3.1.2 Insulin
    5.2.3.1.3 Non-Insulin Injectable Drugs
    5.2.3.1.4 Combination Drugs
    5.2.3.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 Oral Anti-diabetic Drugs
    5.2.3.2.2 Insulin
    5.2.3.2.3 Non-Insulin Injectable Drugs
    5.2.3.2.4 Combination Drugs
    5.2.3.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 Oral Anti-diabetic Drugs
    5.2.3.3.2 Insulin
    5.2.3.3.3 Non-Insulin Injectable Drugs
    5.2.3.3.4 Combination Drugs
    5.2.3.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 Oral Anti-diabetic Drugs
    5.2.4.1.2 Insulin
    5.2.4.1.3 Non-Insulin Injectable Drugs
    5.2.4.1.4 Combination Drugs
    5.2.4.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 Oral Anti-diabetic Drugs
    5.2.4.2.2 Insulin
    5.2.4.2.3 Non-Insulin Injectable Drugs
    5.2.4.2.4 Combination Drugs
    5.2.4.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 Oral Anti-diabetic Drugs
    5.2.4.3.2 Insulin
    5.2.4.3.3 Non-Insulin Injectable Drugs
    5.2.4.3.4 Combination Drugs
    5.2.4.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 Oral Anti-diabetic Drugs
    5.2.4.4.2 Insulin
    5.2.4.4.3 Non-Insulin Injectable Drugs
    5.2.4.4.4 Combination Drugs
    5.2.4.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 Oral Anti-diabetic Drugs
    5.2.4.5.2 Insulin
    5.2.4.5.3 Non-Insulin Injectable Drugs
    5.2.4.5.4 Combination Drugs
    5.2.4.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 Oral Anti-diabetic Drugs
    5.2.4.6.2 Insulin
    5.2.4.6.3 Non-Insulin Injectable Drugs
    5.2.4.6.4 Combination Drugs
    5.2.4.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 Oral Anti-diabetic Drugs
    5.2.4.7.2 Insulin
    5.2.4.7.3 Non-Insulin Injectable Drugs
    5.2.4.7.4 Combination Drugs
    5.2.4.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 Oral Anti-diabetic Drugs
    5.2.4.8.2 Insulin
    5.2.4.8.3 Non-Insulin Injectable Drugs
    5.2.4.8.4 Combination Drugs
    5.2.4.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 Oral Anti-diabetic Drugs
    5.2.4.9.2 Insulin
    5.2.4.9.3 Non-Insulin Injectable Drugs
    5.2.4.9.4 Combination Drugs
    5.2.4.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 Oral Anti-diabetic Drugs
    5.2.4.10.2 Insulin
    5.2.4.10.3 Non-Insulin Injectable Drugs
    5.2.4.10.4 Combination Drugs
    5.2.4.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 Oral Anti-diabetic Drugs
    5.2.4.11.2 Insulin
    5.2.4.11.3 Non-Insulin Injectable Drugs
    5.2.4.11.4 Combination Drugs
    5.2.4.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 Oral Anti-diabetic Drugs
    5.2.5.1.2 Insulin
    5.2.5.1.3 Non-Insulin Injectable Drugs
    5.2.5.1.4 Combination Drugs
    5.2.5.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 Oral Anti-diabetic Drugs
    5.2.5.2.2 Insulin
    5.2.5.2.3 Non-Insulin Injectable Drugs
    5.2.5.2.4 Combination Drugs
    5.2.5.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 Oral Anti-diabetic Drugs
    5.2.5.3.2 Insulin
    5.2.5.3.3 Non-Insulin Injectable Drugs
    5.2.5.3.4 Combination Drugs
    5.2.5.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 Oral Anti-diabetic Drugs
    5.2.5.4.2 Insulin
    5.2.5.4.3 Non-Insulin Injectable Drugs
    5.2.5.4.4 Combination Drugs
    5.2.5.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 Oral Anti-diabetic Drugs
    5.2.5.5.2 Insulin
    5.2.5.5.3 Non-Insulin Injectable Drugs
    5.2.5.5.4 Combination Drugs
    5.2.5.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 Oral Anti-diabetic Drugs
    5.2.5.6.2 Insulin
    5.2.5.6.3 Non-Insulin Injectable Drugs
    5.2.5.6.4 Combination Drugs
    5.2.5.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 Takeda
    7.1.5 Pfizer
    7.1.6 Janssen Pharmaceuticals
    7.1.7 Astellas
    7.1.8 Boehringer Ingelheim
    7.1.9 Merck and Co.
    7.1.10 AstraZeneca
    7.1.11 Bristol Myers Squibb
    7.1.12 Novartis
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca
    7.2.5 Astellas
    7.2.6 Janssen Pharmaceuticals
    7.2.7 Merck and Co.
    7.2.8 Others

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Medical Robots Market 2019 Global Technology, Development Strategy, Trends and Forecasts to 2026

    Global Grid Systems Market 2019: Comprehensive Insight by Growth Rate, Global Trends, Industry Status, Key Players Forecast till 2024,

    Oxcarbazepine Market 2019 | Global Industry Revenue, Key Strategies, Business Growth Rate, Size, Share, and Applications Market Research Forecast to 2023

    Artificial Intelligence in Life Sciences Market 2019 Global Industry Trends, Size, Segments, Competitors Strategy, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2024 Analysis

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *